BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing conditionally active biologic antibody therapies through its proprietary CAB technology platform. Its pipeline includes antibody-drug conjugates and T-cell engaging bispecific antibodies aimed at oncology targets such as AXL, ROR2, CTLA-4, EpCAM, and Nectin-4. The company does not have approved products or a commercial sales organization, so its business is centered on research, clinical development, and licensing collaborations. BioAtla has also used out-licensing to generate collaboration revenue and milestone potential while it continues to fund development of its own product candidates.
0.37
0.37
| % | |
|---|---|
| Clinical-stage oncology drug candidates | 0% Experimental antibody-based cancer therapies in preclinical and Phase 1/2 development. |
| CAB antibody-drug conjugates | 0% Conditionally active ADC programs designed to target tumors while limiting activity in healthy tissue. |
| CAB bispecific antibodies | 0% T-cell engaging and other bispecific antibody programs built on the CAB platform. |
| Licensing and collaboration revenue | 100% Upfront, milestone, and potential royalty income from out-licensing selected programs. |
BioAtla does not currently sell approved products to end customers, so its near-term counterparties are primarily...
Biotechnology or pharmaceutical companies that acquire rights to programs such as BA3362 to develop and commercialize them, paying upfront, milestone, and royalty consideration.
Third parties that fund or co-fund preclinical research and development work tied to specific programs or pre-IND activities.
Hospitals, oncology clinics, and specialists that would prescribe approved therapies if BioAtla or a partner commercializes a product.
Government and commercial insurers that would determine reimbursement and access for any approved oncology product.
BioAtla is headquartered in the United States and currently conducts its business primarily through U.S...
BioAtla’s strategy is to advance its CAB platform into differentiated oncology assets and use clinical data to support...
Clinical data is the main driver of value for a pre-commercial biotech and determines whether programs can be partnered or advanced.
Partnerships can provide funding, external validation, and a path to value realization without building a full commercial organization.
The company disclosed substantial doubt about going concern and expects to need additional funding to continue operations.
Without a sales organization, BioAtla must either build commercial capabilities or rely on third parties to reach patients.
BioAtla is exposed to the classic risks of a clinical-stage biotech: its product candidates may fail in development,...
The company disclosed that current cash may not fund operations for at least twelve months and that it will need substantial additional capital.
Pipeline value depends on successful Phase 1/2 execution and eventual regulatory approval.
The company’s future success is tied heavily to the performance of its patented CAB approach.
BioAtla currently lacks a marketing and sales organization and may need third parties to commercialize any approved product.
Larger competitors may reach approval sooner, and regulators may impose safety, labeling, or REMS constraints.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
CNTX · Pharmaceutical Preparations
BCTX · Pharmaceutical Preparations
BCAX · Pharmaceutical Preparations
APVO · Pharmaceutical Preparations
CABA · Biological Products, (No Diagnostic Substances)
: 11/08/2026